Astellas Pharma Inc (Astellas) has acquired Universal Cells Inc for $102.5m.
The acquirer company is a pharmaceutical company based in the US, while the acquired company, also based in the US, is a biotech company.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acquisition will enable Astellas Pharma to use Universal Cells’ proprietary Universal Donor Cell technology to manufacture cell therapy products in a number of therapeutic areas.
Shenzhen Neptunus Bioengineering has agreed to acquire a 60% share in a medical tech company based in Tianjin for CNY48.6m ($7.69m).
The Chinese pharmaceutical company will complete the transaction through its Ningbo-based trade unit.
Mallinckrodt Pharmaceuticals has completed the acquisition of Sucampo Pharmaceuticals for $1.2bn.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe acquisition was announced in December 2017 and will add Sucampo’s AMITIZA (lubiprostone), RESCULA, VTS-270 and CPP-1X / sulindac products to Mallinckrodt’s portfolio.
Deutsche Bank was appointed as the financial advisor for the transaction by Mallinckrodt, and Wachtell, Lipton, Rosen & Katz as the legal advisor.
Jefferies served as the exclusive financial advisor for Sucampo and Cooley served as the legal advisor for the transaction.
